Adaptive Biotechnologies (ADPT) Earnings Analysis
Adaptive Biotechnologies (ADPT) has no confirmed upcoming earnings date. Last quarter (2026-02-05) it beat with EPS -0.09 USD vs -0.19 USD est (+52.6%). It has beaten estimates in 6/6 recent quarters (100%). Trailing P/E -67.04.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does ADPT next report earnings?
No confirmed upcoming earnings date is currently scheduled for ADPT. This page updates as the calendar is published.
ADPT earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-05 | -0.09 USD | -0.19 USD | +52.6% | Beat |
| 2025-11-06 | 0.06 USD | -0.18 USD | +133.3% | Beat |
| 2025-05-05 | -0.2 USD | -0.34 USD | +41.2% | Beat |
| 2025-02-12 | -0.23 USD | -0.27 USD | +14.8% | Beat |
| 2024-11-07 | -0.22 USD | -0.29 USD | +24.1% | Beat |
| 2024-08-01 | -0.31 USD | -0.33 USD | +6.1% | Beat |
Beat rate: 6/6 (100%) over reported quarters with consensus data.
ADPT valuation and analyst view
| Trailing P/E | -67.04 |
|---|---|
| Trailing EPS | -0.31944 USD |
| Price / book | 15.78 |
| Dividend yield | 0.00% |
| Market cap | 3.52B |
| Analyst consensus | Buy (11 buy / 4 hold / 2 sell) |
| Avg price target | 21 USD |
Related research pages
Frequently asked questions
When is Adaptive Biotechnologies (ADPT)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for ADPT. This page updates as the calendar is published.
Did ADPT beat earnings last quarter?
In its 2026-02-05 report, ADPT posted EPS of -0.09 USD versus a -0.19 USD estimate — a beat of 52.6%.
What is ADPT's earnings track record?
Over the last 6 reported quarters with consensus data, ADPT beat estimates 6 times (100%).
What is ADPT's current P/E ratio and EPS?
ADPT trades at a trailing P/E of -67.04 on trailing EPS of -0.3194422918240623 USD.
What do analysts rate ADPT?
Analyst consensus is "Buy" across 17 ratings (0 strong buy, 11 buy, 4 hold, 2 sell, 0 strong sell). Average 12-month price target: 21 USD.